EU Marketing Authorisation | What are the Steps and Timelines for Centralised Procedure at EMA?| DRA

Поділитися
Вставка
  • Опубліковано 8 лют 2025
  • Welcome to the PharmaCamp with Neha. This is a small initiative from my side to share knowledge about the pharmaceutical world and regulatory, as I feel education is the best gift one can receive or give back to society.
    Are you a working professional who wants to upgrade your skills? OR a student who wants to make a career in pharmaceuticals? OR are you a person who is interested to learn about the regulatory systems? Then this UA-cam channel is for you.
    About me:
    I am Neha Parashar, working as a Associate Director in a pharmaceutical company and based in Germany. I am a passionate healthcare professional, an educator, and a mentor.
    In this video, we will discuss - What are the Steps and Timelines for Centralised Procedure (CP) at EMA?
    Channel Introduction- Welcome to PharmaCamp • Welcome to PharmaCamp ...
    Series 1 -Regulatory Learnings | Investigational New Drug (IND) Application
    What is Clinical Trial? • What is Clinical Trial...
    What is Investigational New Drug (IND) Application • What is Investigationa...
    Step-wise Approach for Investigational New Drug (IND) Application • Step-wise Approach for...
    Step 1: How to prepare the Regulatory Strategies for IND Application? • Step 1: How to prepare...
    Step 2: What is Target Product Profile (TPP)? • Step 2: What is Target...
    Step 3: Meetings with USFDA (Part 1) • Step 3: Meetings with ...
    Step 3: What are the Types of USFDA meetings (Part 2)? • Step 3: What are the T...
    Step 3: What are the Steps for Meetings with USFDA (Part 3)? • Step 3: What are the S...
    Step 3: 10 Tips For Preparation of Successful USFDA Meeting (Part 4)? • Step 3: 10 Tips For Pr...
    Step 4: What content do we include in IND application (Part 1)? • Step 3: 14 Tips to fol...
    Step 4: Types of USFDA forms for IND application (Part 2)? • Step 4: Types of USFDA...
    Step 5: How to submit an Investigational New Drug (IND) application to USFDA? • Step 5: How to submit ...
    Step 6: How does USFDA review an Investigational New Drug (IND) application? • Step 6: How does USFDA...
    Step 6: How does USFDA review an Investigational New Drug (IND) application (Part 2)? • Step 6: How does USFDA...
    Step 7: How are Clinical Trials Registered in USA? • Step 7: How are Clinic...
    Step 8: How to do IND Life Cycle Management? • Step 8: How to do IND ...
    Step 9: Completion of Clinical Trial and Ending an IND. • Step 9: Completion of ...
    Series 2-Regulatory Shorts
    Regulatory Shorts#1 | Vaccines Approval | Expanded Access vs Emergency Use Authorization (EUA) vs “Off-Label” Use. • Regulatory Shorts#1 | ...
    Regulatory Shorts#2 | DSUR vs PSUR | Safety Reports
    Regulatory Shorts#3 |Data Lock Point, International Birth Date, Development International Birth Date. • Regulatory Shorts#3 |D...
    Regulatory Shorts#4 | Orange Book vs Purple Book. • Regulatory Shorts#4 | ...
    Regulatory Shorts#5| Side Effect vs Adverse Drug Reaction vs Adverse Event. • Regulatory Shorts#5| S...
    Regulatory Shorts#6 | Global Expedited Regulatory Pathways. • Regulatory Shorts#6 | ...
    Regulatory Shorts#7 | Patent vs Data Exclusivity vs Market Exclusivity. • Regulatory Shorts#7 | ...
    Regulatory Shorts#8 | How to get Marketing Authorisation in European Union (EU)?. • Regulatory Shorts#8 | ...
    LinkedIn: / neha-parashar
    LinkedIn Articles on various Regulatory Topics:
    1. Regulatory Pathways for Expedited Access of Medicines / regula. .
    2. Step-wise Regulatory approach for the Paediatric drug Development / step-w. .
    3. Designing the Global Regulatory Strategy for the Development of Orphan Medicinal Products
    / design. .
    4. Step wise approach for the Quality Risk Management (QRM) in pharmaceutical industries / step-w. .
    5. Step-wise regulatory approach for the assessment of process related impurities in biological products / step-w. .
    6. Step-wise approach for sterilisation package preparation in regulatory dossiers for biologicals and other liquid sterilised products / step-w. .
    7. Step-wise approach for regulatory risk assessment of adventitious agents in biologicals products / step-w. .
    8. Five Step Approach to Assess the Equivalency Requirements of Topical Products / five-s. .
    Disclaimer- This video channel is for educational purposes. These are purely my views and not any recommendations. The channel does not represent the views of the organization I am associated with, and it has no connection with my current organization.

КОМЕНТАРІ • 31

  • @bapufromUK
    @bapufromUK Рік тому +1

    Nice Neha, best research and very professional way of explanation, Thank you. Will wait for your videos on ATMPs, and CAT !..... Greetings from London.

  • @maheshdesale9373
    @maheshdesale9373 Місяць тому

    Very good explained

  • @avinashkadam6745
    @avinashkadam6745 Рік тому +1

    Explained Very well in lucid language.
    Thank you Neha. There are Very few Or no channels covering Pharma regulatory Segment from filing perspective.
    I would request you to please make one video on regulatory job options in Europe, US, UK etc. please explain along with salary details.
    Thank you. Keep it up.

    • @pharmacamp
      @pharmacamp  Рік тому

      Thanks Avinash. I am very happy to know this 😊. Sure will cover more such topics in future.

  • @Archanakashyapomnamahshivay
    @Archanakashyapomnamahshivay Рік тому +1

    can you please provide the link of your previous video which you are talking in this video; very wonderful explanation; thankyou so much!!!

  • @mrunalipatel1939
    @mrunalipatel1939 2 роки тому +1

    Wonderful explanation mam.
    It's easy to understand and informative...

  • @snehareddy4904
    @snehareddy4904 2 роки тому +1

    Amazing explanation Mam..Thank You

  • @stutikamane4435
    @stutikamane4435 2 роки тому +1

    Precise and complete Information

  • @ashishkokate7862
    @ashishkokate7862 10 місяців тому

    Very good explanation.

  • @shalinijha6890
    @shalinijha6890 9 місяців тому

    Thnks for the information

  • @prashantgrbhardwaj9962
    @prashantgrbhardwaj9962 2 роки тому +1

    Amazing information.

  • @gangadharm1983
    @gangadharm1983 Рік тому +1

    Excellent explanation madam

  • @Anilkumar-ww9gu
    @Anilkumar-ww9gu 9 місяців тому

    Usefull information

  • @vinay6652
    @vinay6652 2 роки тому +1

    Excellent

  • @pranamks5104
    @pranamks5104 7 місяців тому

    Useful

  • @sagarjain1376
    @sagarjain1376 2 роки тому +1

    Can you make video on business development and licensing terms

  • @RaveenaRana-g8y
    @RaveenaRana-g8y 8 місяців тому

    Ma'am how and where we apply for DRA in foreign countries

  • @jagdishchavan3630
    @jagdishchavan3630 11 місяців тому

    For veterinary products we want to go through cp is it compulsory?

  • @pharmaceuticsstudy8603
    @pharmaceuticsstudy8603 Рік тому

    Thank you for the information, I have learnt very much info in a few minutes. can u give me MHRA link or pathway for MA submission?

  • @sandeepbansal1241
    @sandeepbansal1241 2 роки тому +1

    Please make a video on variations

    • @pharmacamp
      @pharmacamp  2 роки тому +1

      Sure Sandeep. I have this topic in the list.

    • @sandeepbansal1241
      @sandeepbansal1241 2 роки тому +2

      Thanks mam, I am also a regulatory professional and working on EU and South African markets. Your videos are very helpful. Do you also provide the webinars?

    • @pharmacamp
      @pharmacamp  2 роки тому +1

      I am happy to know that videos are helpful. Yes the webinar is in plan. Will keep posted.

    • @sandeepbansal1241
      @sandeepbansal1241 2 роки тому +2

      @@pharmacamp really amazing, keep posting😊😊